The San Francisco 49ers' revamped strategy proved successful against the less driven Eagles, enhancing their playoff chances, ...

Enrollment completed across 18 clinical sites with 40+ investigators in the US, Canada, and New Zealand If the GPX ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions The latest update is out from Genprex ( (GNPX) ). On January 6, 2026, Genprex reported positive preliminary ...

(RTTNews) - Genprex Inc. (GNPX) reported positive preliminary preclinical results for its diabetes gene-therapy candidate GPX-002, showing in-vivo proof-of-concept in both Type 2 diabetic non-human ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

Genprex Inc. has released preliminary in vivo proof-of-concept data for GPX-002, the company’s diabetes gene therapy drug candidate, in a nonhuman primate (NHP) model of type 2 diabetes and in a mouse ...

Fluidx Medical Technology, Inc. announced the completion of patient enrollment in the investigational device exemption (IDE) piv ...

(RTTNews) - Genprex, Inc. (GNPX) on Tuesday reported preliminary preclinical data showing its diabetes gene therapy candidate GPX-002 improved glucose control in Type 2 diabetes animal models. In ...

Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc.

Rich Martin is a trainer for British Cycling’s (recently revamped) guiding programme, and he also helps run Cyclewise, which ...